Introduction {#Sec1}
============

Over the last decade, there have been notable improvements in the treatment of acute stroke. While the number of patients surviving stroke is expected to increase, optimal management of post-stroke patients remains problematic^[@CR1]^. Stroke is the most common comorbidity in epilepsy in elderly people^[@CR2]^. Recent reviews have reported acute symptomatic seizure in acute ischemic stroke (AIS), so called "early-onset seizure" (ES), was a risk of post-stroke epilepsy (PSE)^[@CR3]--[@CR5]^. Estimates of the rate of ES in patients with an AIS in the last decade range from 2% to 6.5%^[@CR5],[@CR6]^. Recently, the predicting score of PSE with AIS was published, with ES the most significant risk factor^[@CR7]^.

The lack of robust evidence in previous studies has meant prophylactic use of anti-epileptic drugs (AED) for ES or PSE remains controversial; indeed, current stroke guidelines do not recommend use of AED for such purposes^[@CR8],[@CR9]^. Statin is an inhibitor of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase and a key drug in the management of acute phase or for the prevention of atherosclerotic diseases, including stroke and coronary artery disease, and is thought to possess neuroprotective properties^[@CR10]^. Statin administration can lead to the modification of epileptogenic processes, presumably from its AED effects^[@CR11]--[@CR16]^. Early use of statins reduced the risk of ES in the management of AIS, and was associated with a lower risk of progression of ES into PSE^[@CR11]^; however, the retrospective design and small number of participants in the study meant confounding factors may not have been eliminated. For example, cardioembolic strokes occur in cortical areas more frequently and are treated with statin less frequently in the acute phase. Stroke subtypes should therefore be acknowledged in any retrospective analysis.

There is a paucity of clinical evidence on the association between statin and seizure. We therefore aimed to verify the predisposing factors in ES in patients with AIS from our observational data, as well as clarify the association between statin administration and ES using propensity score (PS) methods.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

All patients admitted to the Department of Stroke and Cerebrovascular Diseases of the National Cerebral and Cardiovascular Center were registered in a database (Clinical Trials.gov: NCT02251665). We identified consecutive patients with AIS admitted within 3 days of onset between August 2012 and July 2016. AIS was defined as the acute onset of focal neurological symptoms lasting 24 h or longer and confirmed by MRI. The following patients were excluded: (i) those diagnosed with epilepsy before index-stroke; (ii) those with stroke due to a trauma, intracerebral hemorrhage, or subarachnoid hemorrhage; (iii) those diagnosed with transient ischemic attack after admission; and (iv) those who did not undergo MRI.

The present study was approved by the Institutional Ethical Committee of the National Cerebral and Cardiovascular Center and conducted in accordance with relevant institutional guidelines. The ethics committee granted a waiver to conduct this study without written informed consent.

Data collection and definitions {#Sec4}
-------------------------------

The collected data included information regarding patient clinical history and presentation, laboratory, imaging, electroencephalographic, treatment, and outcomes \[modified Rankin Scale (mRS) score and mortality\] at discharge. The data collectors were unaware of the current study.

Stroke severity was measured using the National Institutes of Health Stroke Scale (NIHSS) score on hospital admission, and trichotomized into three levels (1, NIHSS \< 9; 2, NIHSS 9--15; 3, NIHSS \> 15)^[@CR17]^. We classified stroke subtypes according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification^[@CR18]^. We estimated vascular territory according to a published atlas^[@CR19]^, and the AIS lesions according to the Alberata Stroke Program Early CT Stroke score for MRI (DWI-ASPECT)^[@CR20]^.

In the current study, patients were recruited if any occurrence of seizure had occurred, after careful evaluation by a trained neurologist(s). ES was defined as a seizure within 7 days of stroke^[@CR21]^. We assessed seizure semiology before treatment, the deterioration of consciousness, and any subtle neurological manifestations in the stroke care unit or stroke ward. An imaging study was performed to exclude recurrence of stroke. Electroencephalography (EEG) was also performed if patients previously had, or were deemed likely to have, seizure. The EEG findings were obtained by two trained neurologists in neurophysiology (S.M., T.T.).

Clinical management {#Sec5}
-------------------

All patients were undergoing treatment for strokes, including antiplatelet agents, anticoagulants, and edaravone as a neuroprotectant, with some having endovascular treatment or decompressive craniectomy, in line with current guidelines^[@CR8]^. Statins were used in patients whose stroke was presumed to be of atherosclerotic origin, including small-vessel occlusion and large-artery atherosclerosis, with or without consideration of the low-density lipoprotein cholesterol level, and not for the prevention of seizure^[@CR8]^. Statin use was classified into two phases: before stroke or in the acute phase. Statin treatment in acute phase was defined as starting within 3 days of index-stroke onset. Types of statin included pitavastatin, atorvastatin, simvastatin, rosuvastatin and pravastatin. AEDs were administered according to the current guidelines on seizures^[@CR22]^ if patients needed treatment, regardless of EEG findings.

Statistical analysis {#Sec6}
--------------------

We examined the differences between the groups using Pearson's chi-square test and Fisher's exact test for categorical data, and Welch's t test and Wilcoxon's rank sum test for continuous variables. All P-values were 2-sided, with P-values of \<0.05 considered statistically significant.

Firstly, logistic regression was used for multivariate analysis of clinical characteristics pertaining to ES, and the associations between ES and clinical outcomes. Pre-specified variables determined to be clinically important were also included in the model.

Secondly, PS were estimated using a logistic regression model. Possible confounders were chosen for their potential association with statin on clinical knowledge. The predicted probability of preprocedural statins was calculated by fitting a logistic regression model, using all clinically relevant variables. PS was used with PS-matching and inverse-probability-of-treatment weighted (IPTW) methods^[@CR23]^. ES and outcome at discharge were analyzed as dependent variables. In PS-matching methods, rigorous adjustment was performed with PS matching using the following algorithm: 1:1 optimal match with caliper width 1/5 logit of the SD and no replacement^[@CR24]^. In the IPTW method, patients were weighted by the inverse probability of receiving statin, the average treatment effect (ATE) and average treatment effect on the untreated (ATT) were estimated by computing the difference between the observed and potential outcomes resulting from the presence and absence of statin treatment for each subject.

Two-hundred sixteen subjects with missing values were excluded from the multivariate and PS analysis. Statistical analysis was performed using R version 3.5.0 (R Core Team (2018). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.).

Results {#Sec7}
=======

General characteristics {#Sec8}
-----------------------

We identified 4595 patients with acute stroke, including intracranial hemorrhage, transient ischemic attack, and 2969 patients with AIS. Of the patients with AIS (1144 males, mean age: 74 ± 12 years old), 1623 (54.6%) were treated with statin (93 only before index-stroke and 1530 in acute phase after admission), and 66 (2.2%) developed ES during the hospitalization. Comparison of the baseline characteristics between the patients with ES (ES group) and those without ES (non-ES group) are shown in Table [1](#Tab1){ref-type="table"}. Compared with the non-ES group, the ES group were older, more dependent (higher mRS), and less likely to have dyslipidemia and higher NIHSS. The C-reactive protein level and white blood cell count were higher in the ES than non-ES group. Cardioembolism was the most common etiology of AIS and was higher for the ES than non-ES group, while small-vessel occlusion was lower for the ES than non-ES group. Regarding imaging characteristics, the ES group had cortical stroke lesion and large vessel stenosis more frequently than the non-ES group.Table 1Baseline characteristics of the study subjects.ES group (n = 66)Non-ES group (n = 2903)P valueBackground  Age, years78.4 ± 9.874.1 ± 12.40.005  Sex, male36 (55)1789 (62)0.252  Body mass index, kg/m^2^20.8 ± 3.722.5 ± 3.8\<0.001  Pre-morbid mRS, point2.5 \[0--4\]0 \[0--2\]\<0.001  Hypertension46 (70)2279 (79)0.096  Dyslipidemia24 (36)1536 (53)0.009  Diabetes mellitus19 (29)735 (25)0.567  Atrial fibrillation21 (32)810 (28)0.489  Past history of stroke27 (41)902 (31)0.106  Congestive heart failure12 (18)349 (12)0.129  Current smoking9 (14)551 (19)0.220  Current alcohol consumption13 (20)1146 (39)\<0.001Laboratory data  LDL-cholesterol, mg/dl106.9 ± 38.6114.9 ± 35.30.069  HDL-cholesterol, mg/dl50.4 ± 14.450.5 ± 14.20.933  Total-cholesterol, mg/dl181.9 ± 43.7190.3 ± 41.10.100  Fasting plasma glucose, mg/dl147.6 ± 70.5136.1 ± 51.60.076  BUN, mg/dl19.8 ± 7.818.7 ± 9.00.324  Creatinine, mg/dl1.2 ± 1.01.1 ± 1.00.409  C-reactive protein, mg/dl1.4 ± 3.80.7 ± 2.10.018  White blood cell count, x10^3^/μl8.3 ± 4.07.2 ± 2.6\<0.001Clinical characteristics  Systolic blood pressure, mm Hg153.3 ± 32.6160.9 ± 38.10.109  Diastolic blood pressure, mm Hg88.1 ± 24.685.5 ± 20.00.396  Initial NIHSS, point12.5 \[5--25.3\]4 \[2--11\]\<0.001  NIHSS severity\<0.001  1, NIHSS ≤ 824 (36)2043 (70)  2, 9 ≤ NIHSS ≤ 1515 (23)296 (10)  3, 16 ≤ NIHSS27 (41)591 (19)Classification of subtype of AIS (TOAST)\<0.001  Small-vessel occlusion1 (1.5)746 (26)\<0.001  Large-artery atherosclerosis12 (18)453 (16)0.606  Cardioembolism32 (49)970 (33)0.012Imaging characteristics  DWI-ASPECTS, point10 \[7--10\]10 \[9,10\]0.055  Hemorrhagic stroke10 (15)461 (16)1.000  Symptomatic hemorrhagic stroke1 (1.5)51 (1.8)1.000  Cortical stroke lesion59 (89)1598 (55)\<0.001  Cortical stroke lesion in the MCA territory54 (82)1321 (46)\<0.001  Cortical stroke lesion in the ACA territory12 (18)293 (10)0.040  Cortical stroke lesion in the PCA territory10 (15)334 (11)0.333  Large vessel occlusion or stenosis33 (50)1458 (50)1.000  Large vessel occlusion27 (38)930 (32)0.309  Large vessel stenosis8 (11)629 (22)0.029Data are presented as mean ± standard deviation, median \[interquartile range\] or absolute (percentage) values. ES, early seizure; mRS, modified Rankin Scale; LDL, low-density cholesterol; HDL, high-density cholesterol; BUN, blood urea nitrogen; NIHSS, National Institutes of Health Stroke Scale; AIS, acute ischemic stroke; TOAST, Trial of Org 10172 in Acute Stroke Treatment; DWI-ASPECTS, Alberata Stroke Program Early CT Stroke score for MRI; MCA, middle cerebral artery; ACA, anterior cerebral artery; PCA, posterior cerebral artery.

Seizure and EEG profile {#Sec9}
-----------------------

Among the 66 patients with ES, 28 (42.4%) had a focal aware seizure, 21 (31.8%) a focal impaired awareness seizure, and 27 (40.9%) a secondary generalized convulsion. Of those with ES, 22 (33.3%) developed status epilepticus. The majority (48 of 66; 72.7%) of all ES occurred during the first 24 hours, 12 (18.2%) occurred during 24 to 48 hours, and 6 (9.1%) occurred 3--7 days after index-stroke. Of 66 patients with ES, 57 (86.3%) had EEG and 20 (30.3%) showed epileptiform discharges. Nine patients with ES did not undergo EEG examination due to the following reasons: the seizure episode taking place out-of-hours for EEG examination in four, too critical medical condition to be eligible for EEG examination in three, and unknown reasons in two.

Treatment and Outcomes at discharge {#Sec10}
-----------------------------------

Comparison of treatment and outcomes at discharge between the ES and non-ES groups are shown in Table [2](#Tab2){ref-type="table"}. There were no differences among the two groups regarding intravenous alteplase, endovascular therapy and edaravone. The ES group received statin less frequently, especially in the acute phase, compared to non-ES group. There were no differences in the timing of statin use (before or after index-stroke) among the two groups. Patients with ES had higher mRS scores than those without ES. Of the 66 patients with ES, 54 were started taking AEDs from the onset of seizure, and 28 patients were them continued at discharge.Table 2Treatment and outcomes at discharge of the study subjects.ES group (n = 66)Non-ES group (n = 2903)P valueIntravenous alteplase9 (14)421 (15)1.000Endovascular therapy5 (10)183 (7.3)0.402Edaravone40 (61)1873 (65)0.517Statin treatment20 (30)1603 (55)\<0.001  Statin use before index-stroke11 (17)764 (26)0.089  Statin use in acute phase19 (29)1511 (52)\<0.001Statin treatment after acute phase22 (33)1673 (58)\<0.001mRS scores at discharge4 \[3--5\]2 \[1--4\]0.009Hospital stay, day25.5 \[18--33.5\]18 \[12--27\]\<0.001In hospital mortality3 (4.6)73 (2.5)0.238Data are presented as median \[interquartile range\] or absolute (percentage) values. mRS, modified Rankin Scale.

Multivariate analysis for ES and outcomes at discharge {#Sec11}
------------------------------------------------------

In logistic regression models adjusted by age, sex, body mass index (BMI), pre-morbid mRS, initial NIHSS, LDL-cholesterol level, subtypes of stroke (TOAST classification), cortical stroke lesion, and statin treatment, cortical stroke lesion \[odds ratio (OR), 2.83; 95% confidence interval (CI), 1.29--7.28; P = 0.008), pre-morbid mRS (per 1 point) (OR, 1.39; 95% CI, 1.18--1.65; P = 0.001), and initial NIHSS (per 10 point) (OR, 1.39; 95% CI, 1.00--1.73; P = 0.046) were higher risks of ES, while statin treatment significantly reduced the risk of ES (OR, 0.44; 95% CI, 0.24--0.79; P = 0.006) (Fig. [1](#Fig1){ref-type="fig"}).Figure 1Adjusted odds ratio for each variable as to ES in multivariate analysis. mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio; CI confidence interval; LDL, low-density cholesterol.

After adjusting for age, sex, BMI, pre-morbid mRS, initial NIHSS, and DWI-ASPECTS, ES was not independently associated with poor functional outcomes (an mRS score of 4-5: OR, 1.29; 95% CI, 0.68--2.49) or mortality (OR, 0.79; 95% CI, 0.18--2.58) at discharge.

Propensity score analysis {#Sec12}
-------------------------

Propensity score (PS) precision was evaluated using a receiver operating characteristic curve, with the area under the curve showing good precision equaling 0.730 (Supplemental Figure). Of patients who received statin, 54.6% (n = 886) were matched to similar patients who did not. The covariate balance in the PS-matched patients was enormously improved (Table [3](#Tab3){ref-type="table"}). When compared to no use, statin reduced the rate of ES significantly by both the PS-matching (OR, 0.23; 95% CI, 0.12--0.46; P \< 0.001) and IPTW method (OR 0.40; 95% CI 0.22--0.75; P = 0.004) (Fig. [2](#Fig2){ref-type="fig"}). Regarding outcome at discharge, poor functional outcome (mRS 4-5) tended to be decreased in patients with statin by both the PS method and IPTW method, but not significantly (PS-matching: OR, 0.74; 95% CI, 0.52--1.03; P = 0.072; IPTW: OR, 0.84; 95% CI, 0.64--1.11; P = 0.227; respectively). In the IPTW method, ATE, representing absolute risk difference of ES in the whole cohort, was 1.9% (statin 1.3% vs. no use 3.2%, P \< 0.001), and ATT, representing absolute risk difference of ES in untreated patients, was 1.7% (statin use 1.2% vs. no statin use 2.9%, P = 0.002).Table 3Patients characteristics of the study subjects before and after PS-matching.VariableBefore PS-matchingAfter PS-matchingstatin (n = 1623)no-use (n = 1345)SMD\*statin (n = 886)no-use (n = 886)SMD\*Age, years72.9 ± 11.275.8 ± 13.40.25074.0 ± 10.974.5 ± 13.50.047Sex, male964 (63)713 (60)0.068542 (61)546 (62)0.042Body mass index, kg/m^2^23.1 ± 3.821.7 ± 3.70.34522.4 ± 3.722.3 ± 3.70.022Pre-morbid mRS0 \[0--1\]0 \[0--2\]0.2020 \[0--2\]0 \[0--1\]0.012Atrial fibrillation327 (20)504 (38)0.411255 (29)244 (28)0.027Past history of stroke537 (33)392 (29)0.077288 (33)279 (32)0.022Current smoking346 (21)214 (16)0.137143 (16)157 (18)0.043Current alcohol consumption671 (41)484 (36)0.108334 (38)339 (38)0.011Systolic blood pressure, mm Hg163.1 ± 28.9157.9 ± 46.50.210158.9 ± 26.8159.3 ± 27.70.014LDL-cholesterol, mg/dl121.8 ± 37.0106.1 ± 31.40.399111.9 ± 34.3111.6 ± 31.50.073Fasting plasma glucose, mg/dl139.9 ± 56.0132.0 ± 46.70.146135.8 ± 52.5134.0 ± 49.20.006C-reactive protein, mg/dl0.56 ± 1.730.97 ± 2.590.2070.71 ± 2.060.63 ± 1.740.036Stroke subtype0.6150.056  Small-vessel occlusion504 (31)243 (19)204 (23)222 (25)  Large-artery atherosclerosis369 (22)111 (8)98 (11)101 (11)  Cardioembolism369 (23)633 (47)312 (35)305 (34)Initial NIHSS score, point3 \[1--7\]6 \[2--18\]0.5564 \[2--10\]4 \[2--10\]0.009DWI-ASPECTS, point10 \[8--10\]10 \[9,10\]0.28910 \[9,10\]10 \[9,10\]0.026Cortical stroke lesion807 (50)849 (63)0.239492 (55)489 (55)0.007Large vessel stenosis446 (27)191 (14)0.286171 (19)159 (18)0.034Data are presented as mean ± standard deviation, median \[interquartile range\] or absolute (percentage) value. PS, propensity score; mRS, modified Rankin Scale; LDL, low-density lipoprotein; DWI-ASPECTS, Alberata Stroke Program Early CT Stroke score for MRI. \*A standardized mean difference (SMD) of ≤0.1 indicates a negligible difference in the measured variables between groups.Figure 2Clinical significances of statin treatment for ES and outcome at discharge in PS methods. PS, propensity score; IPTW, inverse-probability-of-treatment weighted; OR, odds ratio; CI confidence interval; mRS, modified Rankin Score.

Discussion {#Sec13}
==========

The major findings of this study were as follows: (i) cortical stroke lesion, pre-morbid mRS, and initial NIHSS were higher risks for ES, while statin treatment was significantly associated with a lower risk for ES in patients with AIS, and (ii) statin treatment still had a consistent result after adjusting by PS methods.

Several previous studies have reported AIS patients with cortical stroke lesion, higher stroke severity or other comorbidities had acute symptomatic seizures more frequently than those without^[@CR11],[@CR25],[@CR26]^. We found that cortical stroke lesion, higher NIHSS and higher degree of disability, represented by pre-morbid mRS, were independently associated with ES in the study subjects. Our study confirmed these factors also promote ES after AIS.

Recent studies have shown that statin was associated with reduced risk of ES^[@CR11]^ and PSE^[@CR11],[@CR15],[@CR16]^ after stroke. Statin was also associated with a lower risk of epilepsy in the absence of stroke^[@CR12]--[@CR14]^. Our study demonstrates early use of statin reduced ES in two PS analyses, adjusted by baseline characteristics, stroke severity, stroke subtypes, and lipid profile. These findings suggest statin is independently associated with lower incidence of ES than other factors. Using these two methods, confounding factors could be reduced or eliminated by measured covariates^[@CR23]^. The effect size of statin was almost equivalent to that found in previous studies^[@CR11],[@CR15],[@CR16]^. The current study, however, differs from previous analyses by reducing selection biases through the addition of PS analyses, adding robustness regarding the inhibitory effect of statin for ES. Although the rate of ES was relatively low compared to the other ES study^[@CR5],[@CR6],[@CR11]^, it is intriguing that the effect of statin, represented by ATT or ATE, was estimated at 1.9% and 1.7%, respectively.

ES is considered a transient metabolic and biochemical phenomenon, incorporating hypoxia, metabolic dysfunction, global hypoperfusion, hyperperfusion, glutamate excitotoxicity, ion channel dysfunction, and blood-brain barrier disruption in acute phase^[@CR4],[@CR5]^. ES was indicated to be a significant risk factor for PSE in a meta-analysis^[@CR3]^. Experimental studies have provided convincing evidence that statins have a neuroprotective, and anti-seizure, effect. It has been reported that lipophilic statins, such as atorvastatin, pitavastatin and simvastatin, but also hydrophilic statins, including simvastatin, have a suppressive effect on seizure development in an experimental animal model^[@CR27]--[@CR30]^. The possible anti-seizure mechanism of statins may be related to the reduction in neuroinflammation mediated by a decrease in glutamate, pro-inflammatory cytokines (such as interleukin-6, interleukin-10, tumor necrosis factor alpha, and interferon-γ) and action in the nitrergic system^[@CR30]^. In accordance with our findings and a previous study^[@CR11]^, early use of statin was independently associated with a lower incidence of ES, which may be related to one or more of the mechanisms described above.

Regardless of stroke subtype or cholesterol levels, our study suggested that statin imparted a protective effect against ES; however, the risk of statin-induced hemorrhage must also be considered^[@CR31],[@CR32]^. A post-hoc analysis of randomized clinical trials showed patients with ischemic stroke of small-vessel subtypes and treated by high dose of atorvastatin had a higher incidence of hemorrhagic stroke, though hemorrhage risk was not increased in patients with stroke of a large-artery atherosclerosis or cardioembolic origin^[@CR31]^. In addition, active statin therapy was not associated with significant increase in ICH, and had a significant reduction in all stroke and all-cause mortality in a meta-analysis of 31 randomized controlled trials of statin therapy^[@CR32]^. Therefore, future prospective studies testing the effect of statins on early seizure after stroke should be considered with such factors in mind.

We acknowledge some limitations in this study. Firstly, the study was performed in a single-center, with retrospective design, and its observation period was short (only comprising hospital stay). Although the 165 patients were initiated statin after acute phase, the reasons behind why they were not initiated within 3 days could not be found. We also excluded subjects with missing data from the analysis and could not include all potential factors not to start statin, i.e. dysphasia, drug hypersensitivity, progression or recurrence of stroke, infection, etc. Such factors may have caused selection bias and limited generalizability. Secondly, acute statin treatment for stroke is not well-established, and our management of AIS could not be sufficiently aligned to other stroke guidelines, further limiting generalizability. Thirdly, there was potential for misdiagnosis regarding limb-shaking TIA for patients with severe carotid stenosis or occlusion; however, this is a rare phenomenon in carotid disease, and with MRI and EEG assessment by a professional neurologist, the risk of misdiagnosis should be minimized. Fourthly, we could not assess doses or types of statins because of the difficulty in acquiring subjects in each group. The neuroprotective effects of statins likely changed according to different doses and type of drug, for example. The study, however, did demonstrate early use of statins was significantly beneficial, including in low doses of commonly-prescribed types. We hope future prospective studies will be performed to address some of the limitations of the current study.

In conclusion, using PS analysis, this study showed robustly that statin treatment can be associated with a lower risk of ES in AIS.
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